Total number of patients evaluable at each time and proportion with leukoencephalopathy*
| Low Risk | Standard/High Risk | |||||
|---|---|---|---|---|---|---|
| LE/Eval (n) | T1 | T2 | LE/Eval (n) | T1 | T2 | |
| Post 1 IV-MTX | 3/21 | 3 | 1 | 47/23 | 4 | 2 |
| Post 4 IV-MTX | 12/20 | 11 | 6 | 12/21 | 12 | 3 |
| Post 7 IV-MTX | 14/21 | 13 | 9 | 18/21 | 14 | 13 |
| End of Therapy | 8/20 | 7 | 6 | 8/17 | 6 | 5 |
Note.—LE indicates leukoencephalopathy; Eval, evaluated; IV-MTX, intravenous methotrexate.
* Note that quantitative T1 and T2 measurements were acquired at the end of the imaging studies and often suffered from motion of patients, making them inevaluable.